What is HC Wainwright’s Forecast for PLRX FY2029 Earnings?

Pliant Therapeutics, Inc. (NASDAQ:PLRX) – Equities researchers at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Pliant Therapeutics in a note issued to investors on Monday, February 10th. HC Wainwright analyst E. Arce forecasts that the company will earn $1.75 per share for the year. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Pliant Therapeutics’ current full-year earnings is ($3.65) per share.

PLRX has been the topic of several other reports. Needham & Company LLC reduced their price objective on shares of Pliant Therapeutics from $38.00 to $10.00 and set a “buy” rating on the stock in a report on Monday. Royal Bank of Canada cut shares of Pliant Therapeutics from an “outperform” rating to a “sector perform” rating and dropped their price target for the company from $45.00 to $4.00 in a research report on Monday. Wells Fargo & Company lowered shares of Pliant Therapeutics from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $41.00 to $4.00 in a report on Monday. Canaccord Genuity Group reaffirmed a “hold” rating and set a $4.00 price objective (down previously from $43.00) on shares of Pliant Therapeutics in a research report on Monday. Finally, Oppenheimer reissued a “market perform” rating on shares of Pliant Therapeutics in a research report on Monday. Seven equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $17.75.

Pliant Therapeutics Price Performance

NASDAQ:PLRX opened at $3.29 on Wednesday. Pliant Therapeutics has a 52 week low of $2.43 and a 52 week high of $18.00. The stock’s fifty day moving average is $11.94 and its two-hundred day moving average is $12.72. The company has a market capitalization of $200.20 million, a P/E ratio of -0.99 and a beta of 1.03. The company has a quick ratio of 10.26, a current ratio of 10.26 and a debt-to-equity ratio of 0.09.

Insider Buying and Selling at Pliant Therapeutics

In related news, General Counsel Mike Ouimette sold 10,230 shares of the company’s stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $10.99, for a total transaction of $112,427.70. Following the sale, the general counsel now directly owns 70,544 shares in the company, valued at approximately $775,278.56. This represents a 12.66 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Hans Hull sold 15,936 shares of the firm’s stock in a transaction that occurred on Friday, January 17th. The shares were sold at an average price of $11.20, for a total transaction of $178,483.20. Following the completion of the sale, the insider now directly owns 211,558 shares in the company, valued at approximately $2,369,449.60. This trade represents a 7.01 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 91,855 shares of company stock valued at $1,026,628 in the last 90 days. Company insiders own 6.40% of the company’s stock.

Institutional Investors Weigh In On Pliant Therapeutics

Large investors have recently modified their holdings of the company. R Squared Ltd acquired a new position in shares of Pliant Therapeutics during the fourth quarter worth $33,000. KLP Kapitalforvaltning AS purchased a new stake in Pliant Therapeutics during the 4th quarter worth about $108,000. Atria Investments Inc purchased a new stake in Pliant Therapeutics during the 3rd quarter worth about $112,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Pliant Therapeutics by 65.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,694 shares of the company’s stock worth $131,000 after acquiring an additional 4,607 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new position in shares of Pliant Therapeutics in the 3rd quarter valued at about $145,000. 97.30% of the stock is owned by hedge funds and other institutional investors.

About Pliant Therapeutics

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.